Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2026-05-12 Declaration of Voting R…
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is a Form 8-K current report containing Item 5.07 “Submission of Matters to a Vote of Security Holders,” which provides the official voting results on each proposal at the annual meeting. It is not the full annual report, audit report, or management discussion, but rather an announcement of shareholder vote outcomes. This matches Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-12 English
S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer)
Regulatory Filings
2026-05-06 English
10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-06 English
ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer)
Annual Report FY 2025
2026-03-20 English
DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)
Remuneration Information Classification · 100% confidence The document is identified as a 'DEFA14A' filing, which corresponds to 'Definitive Additional Materials' related to a proxy statement under Schedule 14A pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is clearly a proxy solicitation related document, not a full report or financial statement. The document length is short (1029 characters), and it is a filing of additional materials to a proxy statement, which fits the Remuneration Information category as proxy statements often include executive compensation details. The presence of 'DEFA14A' and 'Proxy Statement' keywords confirms this classification.
2026-03-20 English
DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)
Proxy Solicitation & Information Statement
2026-03-20 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.